 nt fundament improv appreci lt
macro risk initi coverag buy rate
messag initi coverag buy rate price
target believ within drug distribut group amerisourc benefit
best custom base contract protect mix busi believ
biggest risk macro-ori includ on-going opioid litig
potenti regulatori chang drug price pt impli share eventu
trade roughli ebitda given price target impli
upsid potenti current level believ buy rate appropri
bottom line believ gener disinterest drug wholes busi model
creat posit risk/reward past coupl year investor
lot deal includ drug price brand gener concern potenti
transit net price model pharmedium name good news
brand gener price issu stabil pharmedium contribut
fulli estim believ allow investor focu core
oper ancillari busi perform well believ
well posit impress balanc sheet sub leverag roughli
yield believ manag grow tire pharmedium distract
eventu look grace exit evidenc current strateg review
busi lastli portfolio get prune balanc sheet continu
improv believ potenti combin walgreen
wide report wsj cnbc provid ad support floor valuat
appreci risk around potenti transit net price model linger opioid
overhang believ current valuat risk/reward tilt upsid
invest posit highlight follow invest posit lot bad news
alreadi stock core distribut ancillari busi perform well
expect eventu sale pharmedium well posit solid custom contract
protect transit biosimilar strong balanc sheet cash flow yield like
attract
invest risk highlight follow invest risk transit net price
model could neg impact profit greater gener deflat
continu sale better outcom increas invest hard
quantifi opioid overhang
valuat price introduc ep estim
respect price target impli share eventu trade
roughli ebitda estim multipl well
year histor averag believ appropri given linger concern
outlin given price target impli roughli upsid potenti current
level believ buy rate appropri
page analyst certif import disclosur
one three larg global pharmaceut sourc distribut servic compani us compani
distribut comprehens offer pharmaceut over-the-counter product home healthcar suppli equip anim health product
outsourc compound steril prepar relat servic wide varieti healthcar provid locat us
market custom includ chain retail independ pharmaci mail order pharmaci acut care hospit
health system physician practic medic dialysi clinic long-term care altern site pharmaci veterinarian
other addit compani suppli healthcar provid pharmaceut manufactur assort relat
servic includ reimburs pharmaceut consult servic nich premium logist servic inventori manag
pharmaci autom pharmaci manag compani divid busi two group first larger
pharmaceut distribut strateg global sourc group predominantli includ amerisoucebergen drug corpor
abdc amerisourcebergen specialti group absg pharmedium second global commerci servic
anim health group made variou consult servic busi includ world courier mwi veterinari
capabl extend well beyond sophist logist distinct requir specif diseas state uniqu
class product combin servic expertis compani offer help manufactur healthcar provid
manag opportun challeng segment market longer term expect grow revenu slightli
market owe industry-lead custom base compani aim grow gross profit slightli slower revenu drive
oper leverag gener approxim net incom benefit balanc redeploy capit
includ strateg synergist share repurchas
lot bad news linger concern alreadi stock past four year share essenti
flat versu combin company-specif industri issu weigh share roughli
time-frame ep increas investor anyth show continu growth earn
attribut major rel under-perform mani well-discuss issu overhang share includ brand
gener drug price pharmedium industri pricing/profit etc recent new issu surfac perpetu
overhang share particular transit net price model on-going opioid litig problem
two issu difficult quantifi posit note known least understood investor high level
share trade discount histor forward ev/ebitda averag
distribut ancillari busi perform well core busi perform well enough
off-set oper profit headwind produc pharmedium variou infrastructur invest recent quarter
manag comment exclud hd smith brazil consolid core oper incom would mid-singl
digit model assum modest low-single-digit core oper profit growth rate believ current trend
pharmaceut price specialti pharmaceut sale continu growth ancillari line busi support
assumpt compani segment refer global commerci servic anim health repres
close overal oper profit includ world courier mwi manag believ segment logic
adjac manufactur servic landscap would surpris see compani use busi platform
addit acquisit expect segment outpac growth core pharmaceut distribut busi time provid
benefit overal margin profil
expect eventu sale pharmedium earli announc follow us fda inspect pharmedium
outsourc facil memphi compani voluntarili suspend product facil execut remedi measur memphi
respons major pharmedium outsourc compound volum well year remedi
effort still on-going decid de-risk guidanc remov pharmedium contribut balanc
easi say hindsight difficult acquisit sens manag patienc rectifi
situat start run thin recent call manag comment current conduct strateg review
busi potenti outcom rang increas invest outright sale busi believ sale
busi would potenti remov manag distract overhang share
posit solid custom contract protect transit biosimilar believ key custom busi
mix enabl grow faster market custom everi segment grow faster market
obviou exampl retail segment one also consid independ retail segment esrx
pbm segment florida cancer specialti kaiser hospit segment freseniu fm dialysi segment name
last coupl year renew mani long-term contract top custom particular
note follow key deal contract esrx kaiser
also recent renew deal club june diplomat pharmaci dplo may although length
agreement announc given size custom potenti expand form strateg
agreement exampl benefit take increment busi
addit distribut custom base industry-lead specialti segment also enhanc growth specialti
group combin oncolog franchis plasma vaccin physician offic distribut third-parti logist busi
world courier consist perform team continu strengthen posit undisput leader
page analyst certif import disclosur
nich premium logist continu benefit growth specialti product avail full-lin distribut affirm
valu effici prime vendor model mani product custom across multipl site care includ hospit
health system commun pharmaci
strong balanc sheet cash flow yield like attract note recent ad chang control provis
leverag sizabl provid opportun strateg growth decemb compani roughli net
debt balanc sheet leverag less compani forecast free cash flow continu
approach capit deploy strateg opportunist manag discuss four prioriti invest includ
invest exist busi strateg share repurchas dividend repurchas stock
remain novemb author
consid possibl combin believ prune pharmedium busi
de-lever balanc sheet would look favor end find chang control languag
ad recent proxi quit interest sign time januari compani enter amend
restat employ agreement current name execut offic steven colli chairman presid ceo john chou
evp chief legal busi offic jame cleari evp cfo robert mauch evp group presid
distribut strateg global sourc upon recommend abc independ compens consult approv
compens success plan committe board director compani employ agreement amend
restat align sever chang control benefit gener market practic support benchmark among
compani peer group event chang control aforement member manag team would receiv
averag salari bonu past three year suggest transact immin broader industri
continu consolid continu believ transact possibl
transit net price model could neg impact profit overwhelm major brand
distribut contract manufactur fee-for-servic ff arrang potenti shift net price model signific
area concern profit percentag embed current ff agreement base drug higher list price suggest
regulatori action chang transpar law price mechan distributor would go back renegoti
ff agreement agre manufactur valu ultim pay fair valu distributor servic
offer hard press believ distributor make widespread renegoti process unscath posit
note estim brand repres less one-third compani profit accordingli expect volatil
process manag time
greater gener deflat lower brand inflat would neg impact profit manag continu articul
gener deflat rel stabl mid- high-singl digit rang believ recent trend industri commentari offer
hope gener deflat start drift back toward mid-singl digit rang manag continu satisfi
brand inflat environ trend mid-single-digit territori much regulatori scrutini brand manufactur
hard see environ go back higher level experienc said absent meaning legisl
hard press assum level inflat slow meaning current level bigger concern us continu
strain price environ gener side three larg purchas group effect take advantag
fragment manufactur side equat difficult predict deflat pressur abat take
comfort fact compani industri suggest level deflat start moder
pharmedium remedi continu best outcom sale view reflect back manag seem
confid pharmedium would tailwind believ remedi measur go take longer cost
initi expect estim pharmedium roughli headwind ebit compani
confer call manag comment memphi facil would open compani expect busi
lose money certainli disappoint believ total unexpect contribut
busi essenti remov guidanc also call manag suggest conduct strateg
oper review busi could result anyth rang increas invest outright sale busi
quit encourag view compani least put option sell busi tabl believ sale
like outcom believ sale would view quit favor investor convers increas invest
would like eat near-term profit weigh investor sentiment
hard quantifi opioid overhang continu vigor defend issu surround opioid epidem
us expect opioid litig advanc court system throughout addit one mani defend
name currently-known trial monetari fine compani like assign portion overal fine
stock perspect believ outcom trial may view posit disciplinari action like overlook
investor one-tim monetari fine said believ import issu monitor litigation/settl
incorpor requir chang oper would increas cost oper infrastructur
page analyst certif import disclosur
valuat risk
valu primarili util ev/ebitda valuat metric although also consid price earn assess multipl
rel histor averag industri peer context current oper futur outlook compani industri
backdrop believ ev/ebitda common metric evalu valuat appropri reflect lack
leverag balanc sheet price target impli share eventu trade roughli ebitda estim
current valuat ebitda rel line peer group averag view adequ
reflect better fundament earn growth profil note target valuat multipl well histor averag
appropri view given linger concern outlin given price target impli roughli upsid
current level believ buy rate appropri
mention previous rate share buy given custom base contract protect mix busi
view key risk thesi combin two long-term black swan event describ opioid litig
potenti regulatori chang risk would opioid litig regulatori chang come fruition earlier
neg way expect
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic
corpor wal-mart inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori amerisourcebergen corpor
rate price target histori diplomat pharmaci inc dplo
creat bluematrix
creat bluematrix
page analyst certif import disclosur
